Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

President Biden’s Proposal To Expand Medicare Price Controls A Sign Of Things To Come

Executive Summary

Even though it is unlikely that the policies will succeed in the currently divided Congress, the proposal reinforces industry’s concerns that once a foundation for Medicare price negotiation is established, policymakers will try to build on it.

You may also be interested in...



Biden’s Pharma Plans Keep Industry Fighting On All Fronts

President’s State of the Union address doubled down on his desire to expand on the IRA. While the agenda poses no near-term threat, it will keep pharma on its toes as industry juggles implementation of the new Medicare prices with fighting the IRA in court and trying to reform the original law.

Medicare Negotiation And The Politics Of Drug Pricing

Medicare pricing decisions will become ‘highly politicized,’ Scott Gottlieb predicts. The former FDA commissioner and CMS official also believes the program should rely on outside health technology assessment groups, and he offers his opinions on how negotiation will (or won’t) change patent litigation.

Ease The Pain – Making Payment Models, Tech, Integration Work For Patients

Multiple payment models, including differential pricing for pooled purchases, and technology-based healthcare platforms are some of the ways to build a patient-centric ecosystem said officials from Roche, VCs and non-government bodies at a recent conference

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel